Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 7.27
- Piotroski Score 3.00
- Grade N/A
- Symbol (BIOS)
- Company BioPlus Acquisition Corp.
- Price $10.80
- Changes Percentage (-0.05%)
- Change -$0.01
- Day Low $10.79
- Day High $10.80
- Year High $11.68
BioPlus Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses in the life sciences industry. The company was incorporated in 2021 and is based in New York, New York.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/30/2023
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.21
- Trailing P/E Ratio 51.404761904762
- Forward P/E Ratio 51.404761904762
- P/E Growth 51.404761904762
- Net Income $5.16 M
Income Statement
Quarterly
Annual
Latest News of BIOS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Is Harmony Biosciences Holdings, Inc. (HRMY) the Best Cheap Growth Stock to Buy According to Analysts?
An article discusses the market response to the recent Federal Reserve rate cuts and insights from Tom Lee on market behavior pre-election. It also highlights Harmony Biosciences as a cheap growth sto...
By Yahoo! Finance | 1 day ago -
Jim Cramer on Regeneron Pharmaceuticals Inc. (REGN): 'Leerink Analysts Downgraded Regeneron To A Market Perform Hold After A Negative Eylea 2mg Biosimilar Preliminary Injunction Ruling'
The article discusses Jim Cramer's investing experiences and emphasizes the importance of starting early in the stock market. It also highlights Regeneron Pharmaceuticals Inc. as a strong investment o...
By Yahoo! Finance | 2 days ago -
Stocks To Watch: Harmony Biosciences Sees RS Rating Jump To 84
Learn how to find game-changing stocks by focusing on technical performance. Look for stocks with an RS Rating above 80. Harmony Biosciences shows potential but is currently outside a proper buy zone....
By Investor's Business Daily | 4 days ago